There is an appointed time for everything — including in biotech. There is a time to start a company, a time to wind it down, a time to go public, and a time to delist the stock.

For every hopeful biotech toiling for decades before finally realizing a profit, there are countless others that run out of money or bet on a product that never delivers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • That’s what I love about managers and c-suite, not matter how much they fail, there will always be some sucker out there willing to value very much their failures and incompetence.
    I wish it was the same for pretty much everything else in life!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy